Skip to main content

Table 2 Ranking different potential designs for ivermectin-based tools

From: Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway

Regimen Efficacy Safety Acceptability Compliance Programmatic difficulty R&D costs Implementation costs
High dose, single encounter To be assessed To be assessed + +++ + + Similar to ACT MDA
Existing dose, multiple encounters To be assessed + +++ + +++ + Similar to SMC
Novel long-lasting formulation, single encounter To be assessed To be assessed To be assessed +++ + +++ Similar to SMC but high R&D costs and longer timeframe to availability
  1. ACT artemisinin combination therapies, MDA mass drug administration, SMC seasonal malaria chemoprophylaxis, R&D research and development